分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

iRGD Modified Chemo-immunotherapeutic Nanoparticles for Enhanced Immunotherapy against Glioblastoma

Jing Kuang, Wen Song, Jun Yin, Xuan Zeng, Song Han, Yi-Peng Zhao, Jun Tao, Chuan-Jun Liu, Xiao-Hua He, Xian-Zheng Zhang

Journal:ADVANCED FUNCTIONAL MATERIALS

IF:13.33

DOI:10.1002/adfm.201800025

PMID:

Published:2018-03-05

research field:肿瘤学神经科学免疫学药学

Abstract

Glioblastoma is the most common primary brain tumor in adults and still remains incurable, due to the limited accumulation of drugs in the tumor area. Herein, iRGD-modified nanoparticles, DOX@MSN-SS-iRGD&1MT, are developed for simultaneous delivery of chemotherapeutic agents (doxorubicin, DOX) and immune checkpoint inhibitor (1-methyltryptophan, 1MT) into orthotopic glioma. The nanoparticles are comprised of mesoporous silica nanoparticles loaded with DOX, combined with Asp-Glu-Val-Asp (DEVD) connected 1MT, and finally modified by iRGD. These nanoparticles show the capability of penetrating through blood brain barrier into the tumor area, and significantly improve accumulation of drugs in orthotopic brain tumors with minimal side effects. The nanoparticles also activate cytotoxic CD8 + T lymphocytes and inhibit CD4 + T cells in both GL261 cells cocultured with splenocytes in vitro and GL261-luc orthotopic tumors in vivo. Moreover, the expression of antitumor cytokines IFNα/β, IFN-γ, TNF, IL-17, STING, and GrzB is upregulated while protumor proteins p-STAT3 and IL-10 are downregulated in the brain tumor area. This study demonstrates the advantages of chemo-immunotherapeutic nanoparticles accumulated in the brain tumor area and their effectively inhibiting tumor proliferation, which establishes a delivery platform to promote antitumor immunity against glioblastoma.

本文使用的Yeasen产品

购物车
客服
转染试用